Re-Evaluation of HER2 Status in Metastatic Breast Cancer and Tumor-Marker Guided Therapy with Vinorelbine and Trastuzumab

Publisher： Karger

E-ISSN： 2296-5262|28|2|95-97

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.2, 2005-02, pp. : 95-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence

By Demonty Gaston  

Women's Health, Vol. 3, Iss. 5, 2007-09 ,pp. : 523-528

Future Medicine

Access to resources Recommend Favorite

Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 582-586

Karger

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

John Wiley & Sons Inc

Access to resources Recommend Favorite

Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?

By Santini Daniele   Vincenzi Bruno   Tonini Giuseppe  

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 1-3

Future Medicine

Access to resources Recommend Favorite